Literature DB >> 15971449

Clinical trials referral resource.

John J Wright1, Ken Zerivitz, Amy Gravell.   

Abstract

Mesh:

Substances:

Year:  2005        PMID: 15971449

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  1 in total

1.  Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.

Authors:  Ying C Henderson; Soon-Hyun Ahn; Ya'an Kang; Gary L Clayman
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.